On September 13, a traveler carrying measles moved through Philadelphia International Airport over nearly five hours, passing between terminals and leaving behind a trail of potential exposures. Six days later, the city’s health department issued a warning. The warning named one person. The problem it revealed was far larger.
That gap — between the visible event and its systemic implications — captures where the United States now stands on measles. This is no longer a story about isolated outbreaks being swiftly contained. It is a story about a country that eliminated measles in 2000, spent a quarter-century treating that achievement as permanent, and is now watching it erode in real time, driven by falling vaccination rates, a hollowed-out public health infrastructure, and a political environment that has made vaccine skepticism not merely tolerable but fashionable in some circles.
The thesis here is straightforward: the United States has not simply experienced a bad outbreak year. It has crossed a threshold, and the conditions for measles to become endemic — circulating continuously rather than arriving in containable imported chains — are now visibly present. Whether the country acts on that recognition is a political choice as much as a public health one.
The numbers make the scale undeniable. Pennsylvania alone has confirmed 890 measles cases as of September 26, with four deaths — the state’s first measles fatalities in thirty-five years. Nationally, 3,659 cases have been recorded across 47 jurisdictions as of September 24. Each major outbreak of 2025 and 2026 — in Texas, Utah, South Carolina, and Pennsylvania — has been larger and longer than anything seen since elimination was declared. These are not anomalies clustering around a stable baseline; they are a trend line moving in one direction.
The Philadelphia airport exposure illustrates the operational cost of that trend with particular clarity. Dr. Matthew Ferrari, director of the Center for Infectious Disease Dynamics at Penn State, described the exposure as “news buzz” in epidemiological terms — the kind of event that rarely produces secondary cases. But operationally, it is punishing. Airport exposures generate large numbers of people who develop routine fevers after passing through a terminal, each of whom must be tracked down, tested, and cleared. The vast majority will turn out not to have measles. The work of ruling them out is real regardless. Each such episode costs a public health workforce — already stretched, already making triage decisions — time and capacity it cannot easily spare. A single outbreak costs an average of more than $750,000 to investigate and contain. “For a response that is already strapped for resources,” Ferrari said, “this is a hit they shouldn’t have to take.”
That workforce strain does not exist in a vacuum. It is the product of decades of underinvestment in public health infrastructure, accelerated by the post-pandemic political backlash against the agencies and institutions that managed COVID-19. The federal government has reduced funding and staffing at the Centers for Disease Control and Prevention under the current administration, precisely at the moment when the epidemiological signals demand more capacity, not less. Scrutinizing that choice is not partisanship — it is arithmetic.
The deeper structural problem is the collapse of vaccination coverage. Measles requires roughly 95 percent of a population to be immunized to sustain herd immunity and prevent the virus from finding enough susceptible hosts to keep spreading. MMR vaccination rates among kindergartners have now fallen below that threshold nationally, with significant geographic variation that creates pockets of vulnerability large enough to sustain prolonged transmission. Those pockets did not form by accident. They formed in communities where vaccine hesitancy was allowed to grow, where misinformation went unchallenged, and where public health messaging was undermined by figures in positions of authority who should have known better — and in some cases did know better.
Ferrari’s framing is precise and worth dwelling on. “The fact that we’ve had multiple of these certainly implies that we have the conditions for endemic persistence,” he said — the conditions, not yet the confirmed reality. That distinction matters because it identifies where the country still has agency. Endemic persistence means measles circulates continuously in the United States, no longer dependent on imported cases to restart transmission. The country is not there yet. But the epidemiological architecture for it — declining immunity, strained response capacity, politically contested vaccination norms — is now in place.
What is required to reverse that architecture is not complicated to describe, even if it is difficult to execute. Vaccination rates must be restored above the herd immunity threshold, which means both strengthening school immunization requirements and investing in the community health workers who can reach families that have drifted toward hesitancy. Public health agencies need sustained, adequate funding — not emergency appropriations after the next outbreak, but structural investment that allows them to maintain capacity between crises. And the political environment that has normalized vaccine skepticism needs to be confronted directly, not managed with false equivalence between the scientific consensus and its critics.
A disease that was eliminated within living memory is reasserting itself because the systems built to prevent that from happening have been allowed to weaken. That is not an act of nature. It is the consequence of choices — about funding, about political speech, about what government is for. The conditions for endemic measles are present. Whether they become the reality depends on whether the country is willing to make different choices than the ones that produced this moment.